Regeneron Hits 52-Week High as Q3 EPS Tops Consensus by 24%
REGN sits 54% above its 52-week low of $591.52 on elevated volume (2.3× avg).
Summary
Regeneron's Q3 adjusted EPS of $20.07 came in well above the $16.19 consensus, and revenue of $5.116 billion beat the $4.542 billion estimate on record Dupixent, Eylea HD and Libtayo sales. Shares jumped 11.46% to $912.63, a new 52-week high. Eylea HD US net sales rose 62% to a record $699 million and now make up nearly two-thirds of the US retinal franchise; Libtayo global sales climbed 51% in constant currency to $550 million. The beat was helped by higher Sanofi collaboration revenue after the Q2 repayment of the development balance, which lets Regeneron recognize its full share of collaboration profits — the same Sanofi pact expanded on October 1. Management guided Q4 Eylea HD physician unit demand up about 10% sequentially and full-year Eylea HD net sales up more than 50%, while flagging a low-to-mid-teens sequential decline in older Eylea demand and rising aflibercept biosimilar competition. A potential FDA approval of the Eylea HD prefilled syringe is the next item that could support 2027 growth.
At the time of this announcement, REGN was trading at $910.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.7B. The 52-week trading range was $591.52 to $935.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.